Emerging retatrutide, a dual -action medication targeting both GLP-1 and GIP receptors, is sparking considerable interest within the medical community. Early clinical trials have revealed significant decreases in overall mass and advancements in physiological markers for people with overweight. Experts believe this ground-breaking approach has t… Read More